-
1 Comment
PolyNovo Limited is currently in a long term downtrend where the price is trading 16.9% below its 200 day moving average.
From a valuation standpoint, the stock is 94.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 72.7.
Finally, its free cash flow fell by 72.3% to $-2M since the same quarter in the previous year.
Based on the above factors, PolyNovo Limited gets an overall score of 1/5.
| ISIN | AU000000PNV0 |
|---|---|
| Industry | Medical Devices |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 1.5 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | None |
| Market Cap | 764M |
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MFJ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
